Introduction Nucleic acid therapies can regulate the expression level or activity of disease-related targets at the genetic level, offering advantages such as a wide target range, programmability, and rapid iteration.  However, the wide application of nucleic acid drugs still faces many challenges, including delivery efficiency and off-target effects. To address these challenges, the Oncology-Immunology team …Read More >

Cell migration, invasion, and adhesion are pivotal steps in cancer metastasis.  To support research in this field, WuXi AppTec offers in vitro transwell migration and invasion assays using multiple cell types for assessing cell migratory behavior.  In addition, our in vivo metastasis panel includes a broad range of brain, bone, and liver xenograft models covering …Read More >

WuXi AppTec offers Jurkat reporter cell lines for immunotherapy drug screening.  Our platform includes CD8+, TCR knockout and CD16-expressing Jurkat-NFAT-Luc reporter cell lines, and validated assays (using co-cultures of Raji or A375 tumor cells) to evaluate the activity of CARs, TCRs, and bispecific antibodies.  Leverage our portfolio of reporter cell lines to accelerate your research! …Read More >

Tissue transglutaminase (TG2) is a multifunctional enzyme activated in several pathological conditions, including cancer. WuXi AppTec recently contributed to a study which used a targeted protein degradation strategy to abolish TG2’s myriad of functions. The authors synthesized and characterized a series of VHL-based degraders that reduce TG2 in ovarian cancer cells in a proteasome-dependent manner.

Within the PI3K family, the heterodimer protein comprising the p110-α and p85-α catalytic/regulatory subunits (encoded by PIK3CA and PIK3R1) are essential in the regulation of cellular proliferation and carcinogenesis.  To support the discovery of novel PI3K inhibitors, WuXi AppTec offers a comprehensive platform of biophysical and biochemical assays to accelerate hit finding and lead optimization …Read More >

Protein arginine methyltransferase 5 (PRMT5) is an enzyme which plays an essential role in a wide range of cellular processes.  PRMT5 overexpression has been implicated in many diseases, including cancer, making this protein an important drug target.  To support the discovery of novel PRMT5 inhibitors, WuXi AppTec offers a comprehensive platform of biophysical and biochemical …Read More >

Cyclin-dependent kinase 2 (CDK2) and its respective cyclin E1 and cyclin A2 complexes are essential to driving abnormal growth processes in cancer cells, making these proteins important targets for cancer treatment.  To support the discovery of novel CDK2 inhibitors, WuXi AppTec offers a comprehensive platform of biophysical and biochemical assays to accelerate hit finding and …Read More >

Werner syndrome helicase (WRN) is a key drug target for cancers with microsatellite instability.  To support the discovery of potent and selective WRN inhibitors, WuXi AppTec offers a comprehensive platform of biophysical and biochemical assays to support hit finding and lead optimization efforts targeting WRN.  Our panel of services also include high-quality WRN protein production …Read More >

Oncolytic viruses (OVs) are emerging as a promising therapeutic approach for treating cancer. OVs are capable of both tumor-specific cell lysis and immune stimulation and can be optimized for enhanced tumor selectivity.  WuXi AppTec offers a comprehensive platform of OV-related services, including virus engineering and validation, immune profiling and lysis assays, tumor cell selectivity assays, …Read More >